MERCK & CO., INC. Onderneming Merck & Co., Inc. Euronext Paris
Aandelen
MRK
US58933Y1055
Farmaceutische producten
Vakgebied
- verkoop van farmaceutische producten (69,7%): voor de behandeling van hypertensie, osteoporose, atherosclerose, ademhalingsziekten, bacteriële en schimmelziekten, oogheelkundige en urologische ziekten, acute migraine, haaruitval bij mannen, enz;
- verkoop van vaccins (18%);
- verkoop van diergezondheidsproducten (9,4%);
- overige (2,9%).
De netto-omzet is als volgt geografisch verdeeld: Verenigde Staten (45,9%), Europa/Midden-Oosten/Afrika (24,5%), China (8,8%), Japan (6,1%), Azië/Pacific (6,1%), Latijns-Amerika (4,3%) en overige (4,3%).
Aantal werknemers: 71 000
Verkoop per activiteit
| USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
Pharmaceutical
89,1
%
| 52 005 | 87,7 % | 53 583 | 89,1 % | +3,03% |
Animal Health
9,4
%
| 5 550 | 9,4 % | 5 625 | 9,4 % | +1,35% |
Other
1,5
%
| 1 728 | 2,9 % | 907 | 1,5 % | -47,51% |
Verkoop per regio
| USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
United States
47,4
%
| 27 206 | 45,9 % | 28 480 | 47,4 % | +4,68% |
Europe, Middle East and Africa
22,0
%
| 14 493 | 24,4 % | 13 254 | 22,0 % | -8,55% |
China
11,3
%
| 5 191 | 8,8 % | 6 802 | 11,3 % | +31,03% |
Asia Pacific
5,4
%
| 3 614 | 6,1 % | 3 225 | 5,4 % | -10,76% |
Japan
5,3
%
| 3 629 | 6,1 % | 3 164 | 5,3 % | -12,81% |
Latin America
5,1
%
| 2 582 | 4,4 % | 3 086 | 5,1 % | +19,52% |
Other
3,5
%
| 2 568 | 4,3 % | 2 104 | 3,5 % | -18,07% |
Managers
| Managers | Titel | Leeftijd | Van |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 01-04-14 |
| Director of Finance/CFO | 55 | 01-01-90 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-08-20 |
Joseph Romanelli
IRC | Investor Relations Contact | 50 | 01-01-96 |
Peter Dannenbaum
IRC | Investor Relations Contact | - | 01-07-17 |
Andre Musto
PRN | Corporate Officer/Principal | - | 01-07-14 |
Brooke Hinkson
PRN | Corporate Officer/Principal | - | 01-08-15 |
Carol Bowden
PRN | Corporate Officer/Principal | - | 01-04-14 |
Dalton Smart
AUD | Comptroller/Controller/Auditor | 58 | 01-11-09 |
James Matteucci
PRN | Corporate Officer/Principal | - | 01-01-03 |
Besturend
| Besturend | Titel | Leeftijd | Van |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 27-11-07 |
Pamela Craig
BRD | Director/Board Member | 67 | 01-09-15 |
Inge Thulin
BRD | Director/Board Member | 69 | 01-03-18 |
Patricia Russo
BRD | Director/Board Member | 71 | 01-09-95 |
| Director/Board Member | 69 | 26-05-20 | |
Robert Davis
CEO | Chief Executive Officer | 57 | 01-04-14 |
Douglas Baker
BRD | Director/Board Member | 65 | 24-05-22 |
Stephen Mayo
BRD | Director/Board Member | 62 | 15-03-21 |
Kathy Warden
BRD | Director/Board Member | 52 | 16-03-20 |
| Director/Board Member | 71 | 16-03-20 |
Aandelenklasse
| Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
|---|---|---|---|---|---|
| Aandeel A | 1 | 3 577 208 962 | 2 531 418 332 ( 70,77 %) | 1 044 402 655 ( 29,20 %) | 70,77 % |
Participaties
| Naam | Aandelen | % | Totale waarde |
|---|---|---|---|
| 13 443 693 | 10.32% | 295 909 530 $ | |
| 1 739 768 | 5.15% | 26 914 211 $ | |
XILIO THERAPEUTICS, INC. 4.02% | 1 483 414 | 4.02% | 1 602 087 $ |
EVAXION BIOTECH A/S 12.13% | 2 297 884 | 12.13% | 843 323 $ |
Bedrijfsgegevens
Bedrijven van de groep
| Naam | Categorie en sector |
|---|---|
MSD Regional Business Support Center GmbH
 MSD Regional Business Support Center GmbH Miscellaneous Commercial ServicesCommercial Services Part of Merck & Co., Inc., MSD Regional Business Support Center GmbH is a German company that provides management consulting services. The company is based in Munich, Germany. Jutta König has been the CEO of the company since 2021. |
Miscellaneous Commercial Services
|
Merck Holdings, Inc.
| |
MSD International GmbH (Switzerland)
 MSD International GmbH (Switzerland) Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD International GmbH (Switzerland) is a Swiss company that discovers, develops and markets human and animal health products. The company is located in Switzerland. |
Pharmaceuticals: Major
|
Schering Plough International Finance Co. BV
| |
MSD Human Health Holding BV
 MSD Human Health Holding BV Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD Human Health Holding BV discovers, develops and markets human and animal health products. The company is based in Oss, Netherlands. |
Pharmaceuticals: Major
|
Merck Sharp & Dohme LLC
 Merck Sharp & Dohme LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme LLC is a pharmaceutical company. The company is based in Kenilworth, NJ. |
Pharmaceuticals: Major
|
Merck Sharp & Dohme Corp.
 Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. |
Pharmaceuticals: Major
|
Essex Chemie AG
| |
Merck Sharp & Dohme BV
 Merck Sharp & Dohme BV Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme BV is a Dutch company that manufactures and distributes pharmaceutical products. The company is based in Haarlem, the Netherlands. |
Pharmaceuticals: Major
|
Sector
Verkoop per activiteit
Verkoop per regio
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| +55,19% | 801 mld. | |
| +47,26% | 631 mld. | |
| -6,09% | 359 mld. | |
| +18,40% | 245 mld. | |
| +3,64% | 231 mld. | |
| +12,98% | 219 mld. | |
| +10,86% | 171 mld. | |
| -2,78% | 161 mld. | |
| +1,24% | 121 mld. |
